The MeCo Score™ is the first and only clinically validated prognostic and predictive biomarker test to improve therapy selection for patients with early-stage breast cancer who may benefit from an FDA-approved antifibrotic therapy (1,2,3).
Our landmark Phase 2 clinical study demonstrated that patients with High MeCo Score breast tumors experienced a remarkable improvement in their survival rate for ~10 years after receiving antifibrotic therapy (3,4).
Moreover, the magnitude and duration of survival benefit appear to be unprecedented among all targeted therapies ever trialed for breast cancer using a chemotherapy or endocrine therapy backbone (3,4).
Partnerships & Collaborations
Funding
Awards & Affiliations
References
[1] Watson, A.W. et al. (2021). Cell Reports. 29;35(13):109293. doi: 10.1016/j.celrep.2021.109293
[2] Data on file with Cleveland Clinic and MeCo Diagnostics Holdings, Inc.
[3] Quintela-Fandino, M. et al. (2024). Clinical Cancer Research. doi: 10.1158/1078-0432.CCR-24-1518
[4] Event-free survival (EFS) after antifibrotic therapy + chemotherapy vs. chemotherapy alone.
Note: the prescribing information for the FDA-approved therapy may not include the associated biomarker, and the proposed intended use for the MeCo Score is subject to change.
*The MeCo Score (TM) assay is for Investigational Use Only
and is not cleared or approved by the US Food and Drug Administration.
Copyright © 2024 MeCo Diagnostics Holdings, Inc. - All Rights Reserved.